文献速递造血干细胞移植与细胞治疗淋巴瘤白血病

减轻不平等:合乎伦理地为CAR-T细胞治疗患者安排优先顺序

Mitigating inequity: ethically prioritizing patients for CAR T-cell therapy.
PubMed 文献 · Blood · 2023-01-01

本文讨论在CAR-T治疗名额有限的情况下,应用「合理性问责」(A4R)这一基于程序正义的优先排序框架来公平分配治疗机会。作者机构成立多学科工作组,通过多轮合作伙伴参与,确定医疗获益、安全/并发症风险、心理社会因素和医疗紧迫性四项优先标准,并开发相应工具与实施流程。作者强调公平与公正伦理原则要求卫生系统采取一致方法,不使医疗资源匮乏或代表性不足人群处于不利地位,并将工具公开供他人参考。

要点

  • CAR-T治疗名额有限时,需用伦理框架确保公平公正决策。
  • 应用A4R框架确定医疗获益、安全/风险、心理社会因素和医疗紧迫性四项优先标准。
  • 作者将工具公开,供其他机构参考开展自身A4R流程。

核心结论

  • 在CAR-T治疗名额有限的情况下,应用A4R优先排序框架可支持公平公正的决策。
  • 公平与公正伦理原则要求卫生系统采取一致方法,不使医疗资源匮乏或代表性不足人群处于不利地位。
  • 作者将工具公开供他人参考,以开展自身A4R流程并根据独特环境调整工具。

研究设计与样本

  • 本文为观点文章(perspective),讨论A4R框架在作者机构CAR-T名额有限问题上的应用。
  • 作者成立覆盖多种血液系统恶性肿瘤的多学科工作组,通过多轮合作伙伴参与开展工作。

主要发现

  • 工作组使用A4R指导原则确定四项CAR-T优先标准:医疗获益、安全/并发症风险、心理社会因素和医疗紧迫性。
  • 开发了与四项标准相关的措施/工具及实施流程。

关键数值与推荐

  • CAR-T优先排序的四项标准为医疗获益、安全/并发症风险、心理社会因素和医疗紧迫性。

临床怎么用

  • 作者将工具公开,理想情况下供他人开展自身A4R流程并调整工具以适应其独特环境。
  • 作者希望其初步工作能支持全球范围内该领域的进一步研究,旨在为所有潜在CAR-T候选者实现资源分配的公正。

局限性

  • 原文将本文工作描述为初步工作(preliminary work),并希望其能支持该领域进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Manufacturing capacity and institutional infrastructure to deliver chimeric antigen receptor T-cell therapies (CAR-T) are pressured to keep pace with the growing number of approved products and expanding eligible patient population for this potentially life-saving therapy. Consequently, many cell therapy programs must make difficult decisions about which patient should get the next available treatment slot. This situation requires an ethical framework to ensure fair and equitable decision-making. In this perspective, we discuss the application of Accountability for Reasonableness (A4R), a priority-setting framework grounded in procedural justice, to the problem of limited CAR-T slots at our institution. We formed a multidisciplinary working group spanning several hematological malignancies. Through multiple rounds of partner engagement, we used A4R guiding principles to identify 4 main criteria to prioritize patients for CAR-T: medical benefit, safety/risk of complications, psychosocial factors, and medical urgency. Associated measures/tools and an implementation process were developed. We discuss further how ethical principles of fairness and equity demand a consistent approach within health systems that does not disadvantage medically underserved or underrepresented populations and supports overcoming barriers to care. In our commitment to transparency and collaboration, we make our tools available to others, ideally to be used to engage in their own A4R process, adapting the tools to their unique environments. Our hope is that our preliminary work will support the advancement of further study in this area globally, aiming for justice in resource allocation for all potential CAR-T candidates, wherever they may seek care.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Bell JAH, Jeffries GA, Chen CI, et al. Mitigating inequity: ethically prioritizing patients for CAR T-cell therapy. Blood. 2023. PMID: 37540818. doi:10.1182/blood.2023020703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。